Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Market Outlook

Thelansis’s “Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Overview

Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal large B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most important test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is a necessity.

• The prevalence of EBV positive DLBCL was 14.0% and 10.4% for EBER cut-off of 20% and 50%, respectively
• The EBV positive DLBCL of the elderly accounts for 8.7%–11.4% of all DLBCL in Asian countries, less than 5% in western nations. Since the introduction of rituximab, R-CHOP has become the standard treatment for CD20 positive DLBCL

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: